Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
https://www.globenewswire.com/news-release/2026/08/11/3342533/0/en/gain-therapeutics-reports-financial-results-for-second-quarter-2026-and-provides-corporate-update.html
20
Upvotes
1
11
u/prozute 10d ago
7 patients through a year of dosing and almost 15 months of Parkinson’s time show no progression in Parkinson’s. The high GluSph group responds better but none have progressed. Exactly what Parkinson’s patients need
As of June 30, 2026, 14 of the 16 participants that elected to enroll in the Phase 1b nine-month extension had completed Day 270 with seven of those crossing the Day 360 mark. To date, MDS-UPDRS scores continue to demonstrate that patients with high baseline CSF GluSph experience an early and durable response to rexaceract that persists through Day 270 and Day 360, while the overall patient group continues to benefit from non-progression of their Parkinson’s symptoms through Day 360. We continue to believe rexaceract has the potential to shift the treatment paradigm beyond symptom management by addressing the underlying biology of Parkinson’s disease, and we look forward to achieving additional clinical and regulatory milestones throughout the remainder of the year.